Linac-based versus MR-guided SBRT for localized prostate cancer: a comparative evaluation of acute tolerability.

Luca NicosiaRosario MazzolaMichele RigoNiccolò Giaj-LevraEdoardo PastorelloFrancesco RicchettiClaudio VitaleVanessa FigliaFrancesco CucciaRuggero RuggieriFilippo Alongi

Published in: La Radiologia medica (2023)

Prostate SBRT with 1.5-T MR-linac is feasible and safe. Compared to conventional linac, MRgRT might to potentially reduce the overall G1 acute toxicity at 6 months, and seems to show a trend toward a lower incidence of grade 2 GI toxicity. A longer follow-up is necessary to assess the late efficacy and toxicity.

Keyphrases

prostate cancer
liver failure
radiation therapy
oxidative stress
respiratory failure
radical prostatectomy
drug induced
aortic dissection
contrast enhanced
magnetic resonance
hepatitis b virus
randomized controlled trial
computed tomography
placebo controlled
extracorporeal membrane oxygenation